Decoy Therapeutics
DCOY
4 hedge funds and large institutions have $111M invested in Decoy Therapeutics in 2015 Q1 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$15.5M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$15.5M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.5M |
| 4 |
Jennison Associates
New York
|
+$15.5M |
Top Sellers
DCOY Hedge Fund Activity: Q1 2015 in Review
4 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q1 2015, worth a combined $111M.
Buyers outnumbered sellers: 4 funds opened new DCOY positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $15.5M.
- 4 institutional investors held Decoy Therapeutics (DCOY) as of Q1 2015, up from 0 in Q4 2014.
- Funds reported $111M of Decoy Therapeutics stock for Q1 2015.
- 4 funds opened new Decoy Therapeutics positions in Q1 2015 and 0 closed out, a net change of +4 holders.
- The largest Decoy Therapeutics buyer in Q1 2015 was Ameriprise, an estimated $15.5M added.
Based on aggregated 13F filings for Q1 2015.